Amgen Inc (AMGN) Price

Amgen Sees High Investor Search Volume

Investor search interest in Amgen (AMGN) is reportedly high, but a lack of specific data makes the cause and market impact unclear.

Amgen Gains FDA Approval for UPLIZNA Treatment

Amgen's stock, which has gained 18.94% in the last three months, received a boost after the FDA approved its drug UPLIZNA for treating generalized myasthenia gravis.

Eli Lilly Leads Dividend Hikes With 15% Increase

Three major healthcare firms, Eli Lilly, Amgen, and Stryker, announced dividend increases in December 2025, with Eli Lilly leading with a 15.3% hike to its quarterly payout.

Amgen Boosts Dividend Payout to $2.52

Amgen Inc. has announced an increased dividend payment of $2.52 per share, payable on March 6th. The move establishes a 3.0% yield, positioning the company as an attractive option for income-focused investors in a market with low average yields.

GSK Pipeline Gains Momentum on Regulatory Wins

GSK plc is gaining significant investor attention after a series of positive regulatory updates in the U.S. and EU for key pipeline assets. These catalysts, combined with an imminent CEO transition, are reshaping the company's narrative from a stable dividend stock to a growth-oriented pipeline story.

Immunovant Shifts Focus With $550M For Autoimmune Drug

Immunovant is now prioritizing its next-generation antibody, IMVT-1402, for Graves' Disease, following a successful $550M capital raise. This strategic pivot sharpens the company's clinical focus and solidifies its financial runway through potential commercialization.

Incyte Board Changes Amid Sector-Wide Leadership Volatility

Hervé Hoppenot, Incyte's former Chairman and CEO, has resigned from the Board of Directors. The departure, though part of a planned transition, occurs as the broader biopharma industry grapples with significant executive turnover and profound regulatory uncertainty at the FDA.

Amgen Uplizna Approval Boosts Autoimmune Pipeline

The U.S. Food and Drug Administration (FDA) has approved Amgen's drug, Uplizna, for treating generalized myasthenia gravis (gMG). This decision expands the drug's market, with analysts projecting blockbuster sales potential due to its competitive twice-yearly dosing schedule.

Zealand Pharma Intensifies Weight-Loss Drug Race

Zealand Pharma announced its "Metabolic Frontier 2030" strategy and a potential $2.5B partnership with OTR Therapeutics. The move aims to challenge leaders Novo Nordisk and Eli Lilly in the rapidly fragmenting, $150B weight-loss drug market, despite a 29% year-to-date stock decline.

Amgen Insiders Liquidate $15M In Stock

Amgen insiders have sold over $15 million in company stock in the past year, a move that may signal caution to shareholders. The most significant transaction came from the company's Executive VP & CTO, prompting investor scrutiny.

US Factory Boom Collides With Import Debate

A significant U.S. manufacturing revival, backed by over $400 billion in new investments, is creating a surge in domestic jobs. However, this industrial boom is running headlong into a persistent consumer affordability crisis, where rising costs and stagnant wages maintain strong demand for cheap imported goods.

Tango Therapeutics Advances Vopimetostat to Pivotal Trial After Positive Cancer Data